)
Visual
test
Foghorn Therapeutics
Foghorn Therapeutics (FHTX) investor relations material
Foghorn Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary11 Mar, 2026
Executive summary
Advanced FHD-909 Phase 1 dose-escalation trial for SMARCA4-mutant cancers, focusing on NSCLC, with enrollment progressing as planned since October 2024.
Selective CBP and EP300 degrader programs are on track for IND-enabling studies in 2026, targeting ER+ breast cancer, multiple myeloma, and DLBCL.
Completed $50 million direct financing in January 2026, extending cash runway into the first half of 2028.
Strengthened executive team with the appointment of a new CFO in February 2026.
Financial highlights
Collaboration revenues rose to $30.9 million for 2025, up from $22.6 million in 2024, driven by the Lilly collaboration.
Research and development expenses decreased to $85.5 million in 2025 from $94.5 million in 2024, mainly due to lower FHD-286 and personnel costs.
General and administrative expenses fell to $27.6 million in 2025 from $28.4 million in 2024.
Net loss narrowed to $74.3 million in 2025 from $86.6 million in 2024.
Cash, cash equivalents, and marketable securities totaled $158.9 million as of December 31, 2025.
Outlook and guidance
Cash runway expected into the first half of 2028, supported by recent financing.
IND-enabling studies for CBP and EP300 degrader programs anticipated in 2026.
Advancing ARID1B degrader program toward in vivo proof of concept in 2026.
Potential combination studies for FHD-909 in NSCLC pending Phase 1 results.
Detail FHD-909 combination strategy in NSCLC
Explain CBPd-171 safety versus dual inhibitors
Update on ARID1B degrader oral delivery progress
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Foghorn Therapeutics
- Pipeline leverages chromatin biology with strong Lilly partnership and promising oncology assets.FHTX
Investor presentation11 Mar 2026 - SMARCA2 clinical progress and pipeline advances position the company for key mid-year decisions.FHTXTD Cowen 46th Annual Health Care Conference3 Mar 2026
- SMARCA2 and CBP/EP300 programs advance, with key clinical milestones expected this year.FHTXGuggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026
- Selective chromatin regulator targeting advances, with promising clinical and pipeline progress.FHTXGuggenheim Securities 2nd Annual Healthcare Innovation Conference3 Feb 2026
- Advancing chromatin-targeted oncology pipeline with key partnerships and strong financial runway.FHTXMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- Advancing chromatin-targeted therapies with clinical and preclinical programs for major cancer indications.FHTXJefferies London Healthcare Conference 202413 Jan 2026
- Advancing chromatin-targeted therapies in AML and SMARCA4-mutant cancers, with new ARID1B focus.FHTX7th Annual Evercore ISI HealthCONx Conference12 Jan 2026
- FHD909 demonstrates strong anti-tumor activity in SMARCA4-mutated NSCLC and pipeline progress.FHTXAACR Annual Meeting 202524 Dec 2025
- Biotech seeks to raise $300M for gene expression-targeted therapies, emphasizing R&D and governance.FHTXRegistration Filing16 Dec 2025
Next Foghorn Therapeutics earnings date
Q1 20266 May, 2026
Foghorn Therapeutics
Next Foghorn Therapeutics earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage